BWXT Announces Sale of Medical Division to Nordic Capital for Up to $800 Million

BWXT Initiates Strategic Sale of Medical Business to Nordic Capital

BWX Technologies, Inc. (NYSE: BWXT) has taken a significant step in its corporate strategy by announcing a definitive agreement to sell its medical operations to Nordic Capital. Valued at up to $800 million, this transaction marks a pivotal moment for BWXT, allowing it to refocus its resources and capital towards its primary interests in nuclear national security and commercial nuclear power markets.

Details of the Transaction

The sale encompasses not only BWXT Medical but also Kinectrics' established medical isotopes business. This agreement underscores BWXT's commitment to maintaining a minority stake in the newly formed entity, ensuring its continued involvement in the rapidly evolving field of radiopharmaceuticals. Under the stewardship of Nordic Capital, BWXT Medical is slated to expand its capabilities, enhancing its market presence in the field of diagnostic imaging and radiotherapeutic treatments.

President and CEO of BWXT, Rex D. Geveden, expressed optimism regarding the future of BWXT Medical, emphasizing the company’s impressive growth trajectory since its acquisition in 2018. The medical division has nearly tripled its revenue during this period, alongside significant improvements in profitability and product diversity that now includes innovative therapeutic isotopes.

“This transaction enables us to concentrate our efforts on core business areas while facilitating the medical division's growth under the auspices of a dedicated healthcare investor like Nordic Capital,” Geveden stated. He noted the advantages of the transition, with Nordic Capital possessing extensive resources and a deep commitment to enhancing the healthcare sector.

Nordic Capital's Role

Nordic Capital is recognized for its sector expertise in healthcare, with a robust background in investing across pharmaceuticals and life sciences. Christian Hedegaard, a partner at Nordic Capital Advisors, conveyed enthusiasm regarding the potential for significant scaling of BWXT Medical under their guidance. The combination of Nordic Capital's investment acumen and commitment to growth positions BWXT Medical to further advance its innovative offerings in radiopharmaceutical therapy.

The transaction is expected to close by the end of 2026, pending regulatory approvals. Financial advising for BWXT is being managed by Solomon Partners, while legal representation comes from Stikeman Elliott. Nordic Capital has engaged Kirkland & Ellis LLP and McCarthy Tétrault as its legal counsel.

Future Outlook

While the exact timing of the sale's completion hinges on regulatory procedures, both BWXT and Nordic Capital are optimistic about the transaction. BWXT's leadership remains confident in the radiopharmaceutical sector's long-term growth potential. By divesting its medical division, BWXT aims to improve its focus on areas critical to national safety and energy, while also retaining a stake in the evolving market of medical isotopes and radioactive therapies.

As the healthcare landscape continues to shift, this deal symbolizes a strategic redirection for BWXT, emphasizing its commitment to innovation and security in the nuclear sector. The transaction marks a cornerstone moment for both companies, setting the stage for future advancements in radiopharmaceuticals and nuclear services.

Conclusion

This comprehensive move represents a path forward for BWXT Technologies as it seeks to redefine its portfolio and operational focus. While the sale presents new opportunities for both BWXT and Nordic Capital, it also highlights the ever-changing dynamics within the healthcare and nuclear industries, where strategic investments can lead to transformative growth.